Abivax Reports First Half 2025 Financial Performance

Abivax revealed its financial results for the first half of 2025, highlighting increased R&D expenditures. Operating loss deepened to EUR 93.7 million, driven by heightened research costs, especially for Crohn's Disease trials. The company's R&D expenses rose by EUR 13.2 million compared to the previous year. Notably, general and administrative expenses fell slightly, saving EUR 1.6 million.

The balance sheet showed a significant decrease in net financial position, primarily due to reduced available cash. Cash reserves dropped from EUR 144.2 million at the end of 2024 to EUR 60.9 million as of June 2025. Despite financial losses, a public offering concluded in July generated significant proceeds, supporting cash flow projections into late 2027.

Abivax's debt position improved with notable conversions of convertible notes, indicating strategic financial adjustments. These efforts, alongside public offering revenue, provide a buffer for future developments.